Amgen has doubled its range of bispecific T-cell engager (BiTE) drugs with the FDA approval of tarlatamab for advanced small cell lung cancer (SCLC) after a priority revie
The FDA has started a priority review of Amgen’s tarlatamab for small cell lung cancer (SCLC), the lead drug in the company’s pipeline of bispecific T-cell engager (BiTE)